Sun Pharma Q2 FY27: India Sales Up 17%, US Slips 8%
Sun Pharma’s Q2 FY27 revenue rose 11.9% to ₹16,198.7 crore on a 17.3% jump in India formulations, while US sales fell 8.3% and a one-time loss pulled reported profit down 32%.
Sun Pharma’s Q2 FY27 revenue rose 11.9% to ₹16,198.7 crore on a 17.3% jump in India formulations, while US sales fell 8.3% and a one-time loss pulled reported profit down 32%.
The US FDA has approved Sun Pharma’s sBLA for ILUMYA (tildrakizumab-asmn) in adults with active psoriatic arthritis, backed by the Phase 3 INSPIRE-1 and INSPIRE-2 studies. The provider-administered IL-23 inhibitor, approved for plaque psoriasis since 2018, now addresses a US PsA population of about 2.4 million.